ペランパネルによるてんかん治療のストラテジー　第2版

出版社： 先端医学社
著者：
発行日： 2022-09-30
分野： 臨床医学：内科  >  脳神経科学/神経内科学
ISBN： 9784865505580
電子書籍版： 2022-09-30 （第2版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：約3営業日

6,600 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

4,620 円(税込)

購入する

商品紹介

ペランパネルを用いたてんかん治療をおこなううえで必要な知識を網羅したストラテジーシリーズの第2版

目次

  • PART 1　分子病態から探るてんかん原性メカニズム
    　1.WES/WGS/GWASによるてんかんの原因・関連遺伝子の探索
    　2.脳オルガノイドを用いたてんかん原性研究への取り組み
    　3.AMPA受容体をターゲットとした革新的医療創生
    　4.グリア細胞とてんかん原性・発作原性 　

    PART 2　診断の進歩と鑑別のポイント
    　1.てんかん発作型・てんかん分類の診断プロセス
    　2.画像によるてんかんの病因・鑑別診断
    　3.AIによるてんかん診療の支援

    PART 2　診断の進歩と鑑別のポイント
    　1.成人てんかんにおけるペランパネル併用療法の実際
    　2.成人てんかんにおけるペランパネル単剤療法の実際
    　3.小児てんかんにおけるペランパネル単剤療法の実際
    　4.小児てんかんにおけるペランパネル併用療法の実際
    　5.てんかん重積状態へのペランパネル導入の実際
    　6.脳波・薬物動態データからペランパネル治療を考える
    　7.てんかん治療におけるペランパネルの副作用マネジメント

    Part 4　患者背景を考慮したてんかん治療の実際
    　1.発達障害を伴う小児てんかん患者の治療の実際
    　2.新生児および乳幼児のてんかん治療の実際
    　3.女性における妊娠を考慮したてんかん治療の実際
    　4.高齢者てんかんの治療の実際
    　5.睡眠の問題を伴うてんかん患者の治療の実際
    　6.てんかん患者における周術期管理の実際
    　7.精神症状を伴うてんかん患者の治療の実際
    　8.外傷性てんかんの治療の実際

    Part 5　社会参加・復帰に向けたてんかん治療
    　1.てんかん患者の心理評価と社会参加・復帰支援
    　2.てんかん患者の運転免許取得・自動車運転へのアドバイス
    　3.パンデミック時におけるてんかん治療の実際

    Part 6　AMPA型グルタミン酸受容体拮抗薬の今後の展望
    　　　　―薬理学的な特徴とリポジショニング―
    　1. ALSに対するAMPA型グルタミン酸受容体拮抗薬の役割
    　2.脳血管障害におけるAMPA型グルタミン酸受容体の役割
    　3.脳腫瘍とAMPA型グルタミン酸受容体
    　4.中枢神経系におけるαシヌクレインの役割とAMPA型グルタミン酸受容体拮抗薬

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

Part 1 分子病態から探るてんかん原性メカニズム

P.21 掲載の参考文献
1) Scheffer IE, Berkovic S, Capovilla G et al : ILAE classification of the epilepsies : Position paper of the ILAE Commission for Classification and Terminology. Epilepsia 58 : 512-521, 2017
PubMed
2) Botstein D, Risch N : Discovering genotypes underlying human phenotypes : past successes for mendelian disease, future approaches for complex disease. Nat Genet 33 (3S) : 228-237, 2003
 
3) 才田謙, 松本直通 : Mendel遺伝病における "次世代" 遺伝子解析. 医学のあゆみ 266 : 410-415, 2018
Medical*Online
4) Richards S, Aziz N, Bale S et al : Standards and guidelines for the interpretation of sequence variants : a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17 : 405-424, 2015
PubMed
5) Saitsu H, Kato M, Koide A et al : Whole exome sequencing identifies KCNQ2 mutations in Ohtahara syndrome. Ann Neurol 72 : 298-300, 2012
PubMed
6) 1000 Genomes Project Consortium, Auton A, Brooks LD et al : A global reference for human genetic variation. Nature 526 : 68-74, 2015
PubMed
7) Abyzov A, Li S, Kim DR et al : Analysis of deletion breakpoints from 1,092 humans reveals details of mutation mechanisrns. Nat Commun 6 : 7256, 2015
PubMed
8) Tsuchida N, Nakashima M, Kato M et al : Detection of copy number variations in epilepsy using exorne data. Clin Genet 93 : 577-587, 2018
PubMed
9) Truty R, Paul J. Kennemer M et al : Prevalence and properties of intragenic copy-number variation in Mendelian disease genes. Genet Med 21 : 114-123, 2019
PubMed
10) Fromer M, Moran JL, Chambert K et al : Discovery and statistical genotyping of copy-number variation from whole-exome sequencing depth. Am J Hum Genet 91 : 597-607, 2012
PubMed
11) Nord AS, Lee M, King MC et al : Accurate and exact CNV identification from targeted high-throughput sequence data. BMC Genomics 12 : 184, 2011
PubMed
12) Uchiyama Y, Yamaguchi D, Iwama K et al : Efficient detection of copy-number variations using exome data : Batch- and sex-based analyses. Hum Matat 42 : 50-65, 2021
 
13) Ma Y, Chen C, Wang Y et al : Analysis copy number variation of Chinese children in early-onset epileptic encephalopathies with unknown cause. Clin Genet 90 : 428-436, 2016
 
14) Mizuguchi T, Suzuki T, Abe C et al : A 12-kb structural variation in progressive myoclonic epilepsy was newly identified by long-read whole-genome sequencing. J Hum Genet 64 : 359-368, 2019
 
15) Mizuguchi T, Toyota T, Adachi H et al : Detecting a long insertion variant in SAMD12 by SMRT sequencing : implications of long-read whole-genome sequencing for repeat expansion diseases. J Hum Genet 64 : 191-197, 2019
PubMed
16) Mitsuhashi S, Matsumoto N : Long-read sequencing for rare human genetic diseases. J Hum Genet 65 : 11-19, 2020
PubMed
17) International League Against Epilepsy Consortium on Complex Epilepsies : Genome-wide mega-analysis identifies 16 loci and highlights diverse biological mechanisms in the common epilepsies. Nat Commun 9 : 5269, 2018
 
18) Song M, Liu J, Yang Y et al : Genome-Wide Meta-Analysis Identifies Two Novel Risk Loci for Epilepsy. Front Neurosci 15 : 722592, 2021
PubMed
19) Zhou W, Nielsen JB, Fritsche LG et al : Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies. Nat Genet 50 : 1335-1341, 2018
PubMed
20) Ishigaki K, Akiyama M, Kanai M et al : Large-scale genome-wide association study in a Japanese population identifies novel susceptibility loci across different diseases. Nat Genet 52 : 669-679, 2020
 
21) Gramm M, Leu C, Perez-Palma E et al : Polygenic risk heterogeneity among focal epilepsies. Epilepsia 61 : e179-e185, 2020
PubMed
22) Moreau C, Rebillard RM, Wolking S et al : Polygenic risk scores of several subtypes of epilepsies in a founder population. Neurol Genet 6 : e416, 2020
 
P.28 掲載の参考文献
1) Yokoi R, Shibata M, Odawara A et al : Analysis of signal components <500 Hz in brain organoids coupled to microelectrode arrays : A reliable test-bed for preclinical seizure liability assessment of drugs and screening of antiepileptic drugs. Biochem Biophys Rep 28 : 101148, 2021
PubMed
2) Matsuda N, Kinoshita K, Okamura A et al : Histograms of Frequency-Intensity Distribution Deep Learning to Predict the Seizure Liability of Drugs in Electroencephalography. Toxicol Sci 182 : 229-242, 2021
PubMed
3) Ishibashi Y, Odawara A, Kinoshita K et al : Principal Component Analysis to Distinguish Seizure Liability of Drugs in Human iPS Cell-Derived Neurons. Toxicol Sci 184 : 265-275, 2021
PubMed
4) Matsuda N, Odawara A, Kinoshita K et al : Raster plots machine learning to predict the seizure liability of drugs and to identify drugs. Sci Rep 12 : 2281, 2022
PubMed
5) Yokoi R, Shigemoto-Kuroda T, Matsuda N et al : Electrophysiological responses to seizurogenic compounds dependent on E/I balance in human iPSC-derived cortical neural networks. J Pharmacol Sci 148 : 267-278, 2022
 
P.32 掲載の参考文献
1) Huganir RL, Nicoll RA : AMPARs and synaptic plasticlty : the last 25 years. Neuron 80 : 704-717, 2013
PubMed
2) Kessels HW, Malinow R : Synaptic AMPA receptor plasticity and behavior. Neuron 61 : 340-350, 2009
PubMed
3) Malenka RC : Synaptic plasticity and AMPA receptor trafficking. Ann N Y Acad Sci 1003 : 1-11, 2003
PubMed
4) Takahashi T, Svoboda K, Malinow R : Experience strengthening translnission by driving AMPA receptors into synapses. Science 299 : 1585-1588, 2003
PubMed
5) Mitsushima D, Ishihara K, Sano A et al : Contextual learning requires synaptic AMPA receptor delivery in the hippocampus. Proc Natl Acad Sci U S A 108 : 12503-12508, 2011
PubMed
6) Jitsuki S, Takemoto K, Kawasaki T et al : Serotonin mediates cross-modal reorganization of cortical circuits. Neuron 69 : 780-792, 2011
PubMed
7) Mitsushima D, Sano A, Takahashi T : A cholinergic trigger drives learning-induced plasticity at hippocampal synapses. Nat Commun 4 : 2760, 2013
 
8) Miyazaki T, Takase K, Nakajima W et al : Disrupted cortical function underlies behavior dysfunction due to social isolation. J Clin Invest 122 : 2690-2701, 2012
PubMed
9) Takemoto K, Iwanari H, Tada H et al : Optical inactivation of synaptic AMPA receptors erases fear memory. Nat Biotechnol 35 : 38-47, 2017
PubMed
10) Tada H, Miyazaki T, Takemoto K et al : Neonatal isolation augments social dominance by altering actin dynamics in the medial prefrontal cortex. Proc Natl Acad Sci U S A 113 : E7097-E7105, 2016
PubMed
11) Miyazaki T, Kunii M, Tada H et al : Developmental AMPA receptor subunit specificity during experience-driven synaptic plasticity in the rat barrel cortex. Brain Res 1435 : 1-7, 2012
PubMed
12) Miyazaki T, Nakajima W, Hatano M et al : Visualization of AMPA receptors in living human brain with positron emission tomography. Nat Med 26 : 281-288, 2020
PubMed
13) Miyazaki T, Takayama Y, Iwasaki M et al : Epileptic discharges initiate from brain areas with elevated accumulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors. Brain Commun 4 : fcac023, 2022
PubMed
P.37 掲載の参考文献
1) Grone BP, Baraban SC : Animal models in epilepsy research : legacies and new directions. Nat Neurosci 18 : 339-343, 2015
PubMed
2) Rusina E, Bernard C, Williamson A : The Kainic Acid Models of Temporal Lobe Epilepsy. eNeuro 8 : ENEURO. 0337-20. 2021, 2021
 
3) Levesque M, Avoli M, Bernard C : Animal models of temporal lobe epilepsy following systemic chemoconvulsant administration. J Neurosci Methods 260 : 45-52, 2016
PubMed
4) Venceslas D, Corinne R : A Mesiotemporal Lobe Epilepsy Mouse Model. Neurochem Res 42 : 1919-1925, 2017
PubMed
5) Sano F, Shigetomi E, Shinozaki Y et al : Reactive astrocyte-driven epileptogenesis is induced by microglia initially activated following status epilepticus. JCI Insight 6 : e135391, 2021
PubMed
6) Wu XL, Zhou JS, Wang LH et al : Proliferation of NG2 cells in the epileptic hippocampus. Epilepsy Res 152 : 67-72, 2019
PubMed
7) Ye Y, Xiong J, Hu J et al : Altered hippocampal myelinated fiber integrity in a lithium-pilocarpine model of temporal lobe epilepsy : a histopathological and stereological investigation. Brain Res 1522 : 76-87, 2013
 
8) Verhoog QP, Holtman L, Aronica E et al : Astrocytes as Guardians of Neuronal Excitability : Mechanisms Underlying Epileptogenesis, Front Neurol 11 : 591690, 2020
PubMed
9) Wang F, Qi X, Zhang J et al : Astrocytic modulation of potassium under seizures. Neural Regen Res 15 : 980-987, 2020
PubMed
10) Patel DC, Tewari BP, Chaunsali L et al : Neuron-glia interactions in the pathophysiology of epilepsy. Nat Rev Neurosci 20 : 282-297, 2019
PubMed
11) Heuser K, Nome CG, Pettersen KH et al : Ca2+ Signals in Astrocytes Facilitate Spread of Epileptiform Activity. Cereb Cortex 28 : 4036-4048, 2018
PubMed
12) Hiragi T, Ikegaya Y, Koyama R : Microglia after Seizures and in Epilepsy. Cells 7 : 26, 2018
 
13) Andoh M, Ikegaya Y, Koyama R : Synaptic Pruning by Microglia in Epilepsy. J Clin Med 8 : 2170, 2019
 
14) Wu W, Li Y, Wei Y et al : Microglial depletion aggravates the severity of acute and chronic seizures in mice. Brain Bekav Immun 89 : 245-255, 2020
PubMed
15) Wan Y, Feng B, You Y et al : Microglial Displacernent of GABAergic Synapses Is a Protective Event during Complex Febrile Seizures. Cell Rep 33 : 108346, 2020
PubMed
16) Bonetto G, Belin D, Karad6ttir RT : Myelin : A gatekeeper of activity-dependent circuit plasticity? Science 374 : eaba6905, 2021
 
17) de Curtis M, Garbelli R, Uva L : A hypothesis for the role of axon demyelination in seizure generation. Epilepsia 62 : 583-595, 2021
PubMed

Part 2 診断の進歩と鑑別のポイント

P.44 掲載の参考文献
1) 高橋幸利 : てんかんの診断から治療の流れ. 新小児てんかん診療マニュアル, 編集 : 高橋幸利, 診断と治療社, 東京, 2019, pp. 16-23
 
2) 高橋幸利 : 血液などの検体検査. 新小児てんかん診療マニュアル, 編集 : 高橋幸利, 診断と治療社, 東京, 2019, pp. 83-89
 
3) 水牧功一, 井上博 : 失神の診療. 日本心臓病学会誌 2 : 2-18, 2008
 
4) 高橋幸利, 那須裕郷, 山口解冬ほか : 偽発作などの非てんかん発作に間違われやすいてんかん発作. 小児科診療 75 : 1309-1314, 2012
Medical*Online
5) Fisher RS, Cross JH, French JA et al : Operational classification of seizure types by the International League Against Epilepsy : Position Paper of the ILAE Commission for Classification and Terminology. Epilepsia 58 : 522-530, 2017
PubMed
6) International League Against Epilepsy : SEIZURE CLASSIFICATION. EpilepsyDiagnosis. org [https://www.epilepsydiagnosis.org/seizure/seizure-classification-groupoverview.html]
 
7) 久保田裕子 : てんかん発作の分類. 編集 : 高橋幸利, 新小児てんかん診療マニュアル, 編集 : 高橋幸利, 診断と治療社, 東京, 2019, pp. 24-30
 
8) International League Against Epilepsy : Proposed Classification and Definition of Epilepsy Syndromes. [https://www.ilae.org/guidelines/definition-and-classification/proposed-classification-and-definition-of-epilepsy-syndromes/proposed-classification-and-definition-of-epilepsy-syndromes]
 
9) Hancock E, Osborne JP : Vigabatrin in the treatment of infantile spasms in tuberous sclerosis : literature review. J Child Neurol 14 : 71-74, 1999
PubMed
10) Steriade C, Britton J, Dale RC et al : Acute symptomatic seizures secondary to autoimmune encephalitis and autoimmune-associated epilepsy : Conceptual definitions. Epilepsia 61 : 1341-1351, 2020
PubMed
11) 高橋幸利 : 抗NMDA受容体脳炎. 脳科学辞典 [https://bsd.neuroinf.jp/wiki/%E6%8A%97NMDA%E5%8F%97%E5%AE%B9%E4%BD%93%E8%84%B3%E7%82%8E]
 
12) Russ SA, Larson K, Halforl N : A national profile of childhood epilepsy and seizure disorder. Pediatrics 129 : 256-264, 2012
 
13) 伊藤ますみ : 第9章 精神・行動随伴症状, A 疫学. 臨床てんかん学, 編集 : 兼本浩祐ほか, 医学書院, 東京, 2015, pp. 220-221
 
P.51 掲載の参考文献
1) 日本てんかん学会分類・用語委員会編集, 中川栄二ほか監修 : ILAEてんかん分類 : ILAE分類・用語委員会の公式声明. 2018年12月25日 (初版) (https://square.umin.ac.jp/jes/images/jes-image/tenkanbunrui2017.pdf)
 
2) 高梨潤一 : てんかんの診断 神経画像検査 MRI, CT. 日本臨牀 72 : 819-826, 2014
 
P.54 掲載の参考文献
1) Liu G, Xiao R, Xu L et al : Minireview of Epilepsy Detection Techniques Based on Electroencephalogram Signals. Front Syst Neurosci 15 : 685387, 2021
PubMed
2) Emami A, Kunii N, Matsuo T et al : Seizure detection by convolutional neural network-based analysis of scalp electroencephalography plot images. Neuroimage Clin 22 : 101684, 2019
PubMed
3) Scheuer ML, Wilson SB, Antony A et al : Seizure Detection : Interreader Agreement and Detection Algorithm Assessments Using a Large Dataset. J Clin Neurophysiol 38 : 439-447, 2021
PubMed
4) Naganur V, Sivathamboo S, Chen Z et al : Automated seizure detection with non-invasive wearable devices : A systematic review and meta-analysis. Epilepsia : Online ahead of print, 2022
 
5) Mormann F, Andrzejak RG, Elger CE et al : Seizure prediction : the long and winding road. Brain 130 (Pt 2) : 314-333, 2007
 
6) Kuhlmann L, Lehnertz K, Richardson MP et al : Seizure prediction-ready for a new era. Nat Rev Neurol 14 : 618-630, 2018
PubMed
7) Sollee J, Tang L, Igiraneza AB et al : Artificial intelligence for medical image analysis in epilepsy. Epilepsy Res 182 : 106861, 2022
PubMed
8) Abbasi B, Goldenholz DM : Machine learning applications in epilepsy. Epilepsia 60 : 2037-2047, 2019
PubMed

Part 3 てんかん治療におけるペランパネルによる臨床応用の実際

P.59 掲載の参考文献
1) Hanada T, Hashizume Y, Tokuhara N et al : Perampanel : a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia 52 : 1331-1340, 2011
PubMed
2) Rogawski MA, Hanada T : Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist. Acta Neurol Scand Suppl 197 : 19-24, 2013
 
3) Villanueva V, D'Souza W, Goji H et al : PERMIT study : a global pooled analysis study of the effectiveness and tolerability of perampanel in routine clinical practice. J Neurol 269 : 1957-1977, 2022
 
4) Takahashi S, Shimizu K Inaji M et al : Effectiveness of perampanel as a first add-on antiepileptic drug for the treatment of partial epilepsy. Epilepsy Behav 100 (Pt A) : 106492, 2019
 
5) Nishida T, Lee SK, Inoue Y et al : Adjunctive perampanel in partial-onset seizures : Asia-Pacific, randomized phase III study. Acta Neurol Scand 137 : 392-399, 2018
 
6) Villanueva V, Garces M, Lopez-Gonzalez FJ et al : Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting : The FYDATA study. Epilepsy Res 126 : 201-210, 2016
 
7) Krauss GL, Perucca E, Ben-Menachem E et al : Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures : results from phase III extension study 307. Epilepsia 55 : 1058-1068, 2014
PubMed
8) Rektor I, Krauss GL, Inoue Y et al : Assessment of the long-term efficacy and safety of adjunctive perampanel in tonic-clonic seizures : Analysis of four open-label extension studies. Epilepsia 61 : 1491-1502, 2020
 
P.64 掲載の参考文献
1) 山本貴道 : Perampanel : 新規抗てんかん薬の創生から単剤療法に至るまで. 臨床精神薬理 24 : 1033-1048, 2021
 
2) Yamamoto T, Lim SC, Ninomiya H et al : Efficacy and safety of perampanel monotherapy in patients with focal-onset seizures with newly diagnosed epilepsy or recurrence of epilepsy after a period of remission : The open-label Study 342 (FREEDOM Study). Epilepsia Open 5 : 274-284, 2020
PubMed
3) Husni RE, Ngo LY, Senokuchi H et al : Experience of perampanel monotherapy beyond initial titration to achieve seizure freedom in patients with focal-onset seizures with newly diagnosed or currently untreated recurrent epilepsy : Apost hoc analysis of the open-label Study 342 (FREEDOM). Epilepsia Open 7 : 59-66, 2022
PubMed
4) Gil-Nagel A, Burd S, Toledo M et al : A retrospective, multicentre study of perampanel given as monotherapy in routine clinical care in people with epilepsy. Seizure 54 : 61-66, 2018
 
5) Delgado RT, Garcia-Morales I, Parejo-Carbonell B et al : Effectiveness and safety of perampanel monotherapy for focal and generalized tonic-clonic seizures : Experience from a national multicenter registry. Epilepsia 61 : 1109-1119, 2020
 
6) Chinvarurl Y : Aretrospective, real-world experience of perampanel monotherapy in patient with first new onset focal seizure : A Thailand experience. Epilepsia Open 7 : 67-74, 2022
 
7) Vazquez B, Tomson T, Dobrinsky C et al : Perampanel and pregnancy. Epilepsia 62 : 698-708, 2021
PubMed
P.69 掲載の参考文献
1) 藤岡かおる, 金村英秋, 反頭智子ほか : ペランパネルがミトコンドリア病に伴うてんかん発作に奏功した1例. てんかん研究 36 : 644-649, 2019
 
2) Shiraishi H, Egawa K, Ito T et al : Efficacy of perampanel for controlling seizures and improving neurological dysfunction in a patient with dentatorubral-pallidoluysian atrophy (DRPLA). Epilepsy Behav Case Rep 8 : 44-46, 2017
 
3) 山岸裕和, 小坂仁, 長嶋雅子ほか : 難治性てんかんに対するペランパネルの治療効果と副作用の検討. てんかん研究 35 : 693-701, 2018
 
4) Kanemura H : Professor Special Lecture 75th Annual Meeting of the Medical Society of Toho University QOL-Related Factors in Childhood Epilepsy. Toho J Med 8 : 52-60, 2022
 
5) 間浦奈央子, 遠藤文香, 秋山麻里ほか : ペランパネルが発作および行動異常に共に著効したLennox-Gastaut症候群の1例. てんかん研究 38 : 36-42, 2020
 
6) Kanemura H, Sano F, Hoshino H et al : Effects of perampanel on secondary bilateral synchrony and behavioral problems in adolescents with epilepsy showing insufficient response with levetiracetam. Seizure 80 : 131-137, 2020
PubMed
7) Kanemura H, Sano F, Aihara M : Usefulness of perampanel with concomitant levetiracetam for patients with drug-resistant epilepsy. Ezr J Paediatr Neurol 23 : 197-203, 2019
 
8) Kanemura H, Sano F, Hoshino H et al : Efficacy of perampanel in epilepsy patients with autism spectrum disorder. Epilepsy Res 170 : 106550, 2021
PubMed
P.73 掲載の参考文献
1) Shiraishi H, Egawa K, Ito T et al : Efficacy of perampanel for controlling seizures and improving neurological dysfunction in a patient with dentatorubral-pallidoluysian atrophy (DRPLA). Epilepsy Behav Case Rep 8 : 44-46, 2017
 
2) Tahara M, Higurashi N, Narita A et al : Long-term efficacy of low-dose perampanel for progressive myoclonus epilepsy in a patient with Gaucher disease type 3. Brain Dev 44 : 308-312, 2022
 
3) Oi K, Neshige S, Hitomi T et al : Low-dose perampanel improves refractory cortical myoclonus by the dispersed and suppressed paroxysmal depolarization shifts in the sensorimotor cortex. Clin Neurophysiol 130 : 1804-1812, 2019
PubMed
P.79 掲載の参考文献
1) Brophy GM, Bell R, Claassen J et al : Guidelines for the evaluation and management of status epilepticus. Neurocrit Care 17 : 3-23, 2012
PubMed
2) Trinka E, Cock H, Hesdorffer D et al : A definition and classification of status epilepticus--Report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia 56 : 1515-1523, 2015
PubMed
3) Callaway CW, Donnino MW, Fink EL et al : Part 8 : Post-Cardiac Arrest Care : 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 132 (18 Suppl 2) : S465-S482, 2015
 
4) 「てんかん診療ガイドライン」作成委員会編, 日本神経学会監修 : てんかん診療ガイドライン 2018, 医学書院, 東京, 2018
 
5) Kapur J, Elm J, Chamberlain JM et al : Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus. N Engl J Med 381 : 2103-2113, 2019
PubMed
6) Perez DQ, Espiritu AI, Jamora RDG : Perampanel in achieving status epilepticus cessation : A systematic review. Epilepsy Behav 128 : 108583, 2022
PubMed
P.84 掲載の参考文献
1) Hanada T : Ionotropic Glutamate Receptors in Epilepsy : A Review Focusing on AMPA and NMDA Receptors. Biomolecules 10 : 464, 2020
 
2) Minassian BA : The progressive myoclonus epilepsies. Prog Brain Res 213 : 113-122, 2014
PubMed
3) Kalviainen R : Progressive Myoclonus Epilepsies. Semin Neurol 35 : 293-299, 2015
PubMed
4) 厚生労働科学研究費補助金難治性疾患政策研究事業 「希少てんかんに関する調査研究」班 : てんかんの指定難病ガイド 第2版. [https://www.res-r.com/wp-content/uploads/2019/04/Guide-Nanbyo-Epilepsy.pdf]
 
5) 村井智彦, 人見健文, 池田昭夫 : 第2章 疾患の特徴と診療指標 1-12 進行性ミオクローヌスてんかん-成人. 稀少てんかんの診療指標. 日本てんかん学会 (編), 診断と治療社, 東京, 2017, pp. 75-78
 
6) 飯田真太朗, 池田昭夫 : 指定難病最前線 Volume 93 進行性ミオクローヌスてんかん. 新薬と臨床 68 : 1189-1192, 2019
 
7) Schorlemmer K, Bauer S, Belke M et al : Sustained seizure remission on perampanel in progressive myoclonic epilepsy (Lafora disease). Epilepsy Behav Case Rep 1 : 118-121, 2013
 
8) Goldsmith D, Minassian BA : Efficacy and tolerability of perampanel in ten patients with Lafora disease. Epilepsy Behav 62 : 132-135, 2016
PubMed
9) Crespel A, Gelisse P, Tang NP et al : Perampanel in 12 patients with Unverricht-Lundborg disease. Epilepsia 58 : 543-547, 2017
PubMed
10) 大井由貴, 小林勝哉, 人見健文ほか : 皮質ミオクローヌスと歩行恐怖症に低容量ペランパネルが著効したUnverricht-Lundborg病の1例. 臨床神経学 58 : 622-625, 2018
 
11) Oi K, Neshige S, Hitomi T et al : Low-dose perampanel improves refractory cortical myoclonus by the dispersed and suppressed paroxysmal depolarization shifts in the sensorimotor cortex. Clin Neurophysiol 130 : 1804-1812, 2019
PubMed
12) 齋藤和幸, 大井和起, 稲葉彰ほか : 長期経過で持続したLance-Adams症候群の重症ミオクローヌスにペランパネルが奏効した1例. 臨床神経学 61 : 18-23, 2021
 
13) Tojima M, Takahashi R, Neshige S et al : Marked response to perampanel : Adecade-long course of giant somatosensory evoked potentials in Unverricht-Lundborg disease. Clin Neurophysiol 132 : 2329-2331, 2021
 
14) 近藤孝之, 山門穂高, 川又純ほか : 振戦様ミオクローヌスと稀発大発作とをみとめたUnverricht-Lundborg病の成人例. 臨床神経学 49 : 43-47, 2009
 
15) Kanemura H, Sano F, Hoshino H et al : Effects of perampanel on secondary bilateral synchrony and behavioral problems in adolescents with epilepsy showing insufficient response with levetiracetam. Seizure 80 : 131-137, 2020
PubMed
16) Dhir A, Bruun DA, Guignet M et al : Allopregnanolone and perampanel as adjuncts to midazolam for treating diisopropylfluorophosphate-induced status epilepticus in rats. Ann N Y Acad Sci 1480 : 183-206, 2020
PubMed
17) Sullivan BJ, Ammanuel S, Kipnis PA et al : Low-Dose Perampanel Rescues Cortical Gamma Dysregulation Associated With Parvalbumin Interneuron GluA2 Upregulation in Epileptic Syngapl +/- Mice. Biol Psychiatry 87 : 829-842, 2020
PubMed
18) Lanzone J, Ricci L, Tombini M et al : The effect of Perampanel on EEG spectral power and connectivity in patients with focal epilepsy. Clin Neurophysiol 132 : 2176-2183, 2021
PubMed
19) Ahn SJ, Kim TJ, Cha KS et al : Effects of perampanel on cognition and quantitative electroencephalography in patients with epilepsy. Epilepsy Behav 115 : 107514, 2021
PubMed
20) van Kerkoerle T, Self MW, Dagnino B et al : Alpha and gamma oscillations characterize feedback and feedforward processing in monkey visual cortex. Proc Natl Acad Sci U S A 111 : 14332-14341, 2014
PubMed
21) Liguori C, Spanetta M, Izzi F et al : Perampanel Increases Cortical EEG Fast Activity in Child and Adult Patients Affected by Epilepsy : A Quantitative EEG Study. Clin EEG Neurosci 52 : 360-370, 2021
PubMed
P.87 掲載の参考文献
1) Villanueva V, D'Souza W, Goji H et al : PERMIT study : a global pooled analysis study of the effectiveness and tolerabiiity of perampanel in routine clinical practice. J Neurol 269 : 1957-1977, 2022
 
2) Steinhoff BJ, Ben-Menachem E, Ryvlin P et al : Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures : a pooled analysis of three phase III studies. Epilepsia 54 : 1481-1489, 2013
PubMed
3) Gonzalez-Cuevas M, Romero O, Toledo M et al : Effect of adjunctive perampanel on the quality of silepsy Behav Case Rep 7 : 13-15, 2017
PubMed
4) Abenza-Abildua MJ, Suarez-Gisbert E, Thuissard-Vasallo IJ et al : Perampanel in chronic insomnia. Clin Neurol Neurosurg 192 : 105724, 2020
 
5) Noguchi M, Kawai Y : Sleeping time after phenobarbital treatment and the brain levels of gamma-aminobutyric acid and phenobarbital at the regaining of righting response point in ethionine-induced liver-disordered mice. J Toxicol Sci 21 : 113-123, 1996
PubMed
6) Youn SE, Kim SH, Ko A et al : Adverse Events during perampanel adjunctive therapy in intractable epilepsy. J Clin Neurol 14 : 296-302, 2018
PubMed
7) Steinhoff BJ, Klein P, Klitgaard H et al : Behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate : A systematic review. Epilepsy Behav 118 : 107939, 2021
PubMed
8) Goji H, Kanemoto K : The effect of perampanel on aggression and depression in patients with epilepsy : A short-term prospective study. Seizure 67 : 1-4, 2019
 
9) Chen B, Choi H, Hirsch LJ et al : Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy. Epilepsy Behav 76 : 24-31, 2017
PubMed
10) Kawai M, Goji H, Kanemoto K : Aggression as psychiatric side effect of newer AEDs in patients with epilepsy : Cross-sectional study based on Buss-Perry Aggression Questionnaire. Epilepsy Behav 115 : 107546, 2021
PubMed
11) Mula M, Trimble MR, Sander JW : Are psychiatric adverse events of antiepileptic drugs a unique entity? Astudy on topiramate and levetiracetam. Epilepsia 48 : 2322-2326, 2007
 
12) Hasegawa N, Tohyama J : Differences in levetiracetam and perampanel treatment-related irritability in patients with epilepsy. Epilepsy Behav 116 : 107644, 2021
PubMed
13) Villanueva V, Garc6s M, Lopez-Gonzalez FJ et al : Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting : The FYDATA study. Epilepsy Res 126 : 201-210, 2016
 
14) 河合三穂子, 兼本浩祐, 郷治洋子 : Perampanel投与後に精神症状を認めた知的障害を合併するてんかん患者の検討. 精神医学 60 : 1393-1401, 2018
 
15) Kanemoto K Tsuji T, Kawasaki J : Reexamination of interictal psychoses based on DSM IV psychosis classification and international epilepsy classification. Epilepsia 42 : 98-103, 2001
PubMed
16) Hasegawa N, Tohyama J : Positive and negative effects of perampanel treatment on psychiatric and behavioral symptoms in adult patients with epilepsy. Epilepsy Behav 117 : 107515, 2021
PubMed
17) Chung S, Williams B, Dobrinsky C et al : Perampanel with concomitant levetiracetam and topiramate : Post hoc analysis of adverse events related to hostility and aggression. Epilepsy Behav 75 : 79-85, 2017
PubMed
18) Iwaki H, Jin K, Sugawara N et al : Perampanel-induced weight gain depends on level of intellectual disability and its serum concentration. Epilepsy Res 152 : 1-6, 2019
PubMed

Part 4 患者背景を考慮したてんかん治療の実際

P.95 掲載の参考文献
1) 神経発達症群/神経発達障害群. DSM-5 精神疾患の診断・治療マニュアル. 日本精神神経学会 (日本語版用語監修), 高橋三郎, 大野悟 (監訳), 医学書院, 東京, 2015, pp. 31-85
 
2) 中川栄二 : 発達障害とてんかん. 認知神経科学 18 : 9-14, 2016
 
3) 中川栄二 : てんかんと神経発達症の併存例には適切な 診断に基づく包括的治療が必要. PROGRESS IN MEDICINE 38 : 1118-1119, 2018
Medical*Online
4) 中川栄二 : 発達障害とてんかん. 最新醫学 (別冊) 診断と治療のABC, 最新医学社, 東京, 2018, pp. 130-138
 
5) 中川栄二 : 国際抗てんかん連盟 (ILAE) 2017年てんかん分類・発作型分類日本語訳について. てんかん研究 37 : 3-36, 2019
 
6) Rheims S, Herbillon V, Villeneuve N et al : ADHD in childhood epilepsy : Clinical determinants of severity and of the response to methylphenidate, Epilepsia 57 : 1069-1077, 2016
PubMed
7) Buckley AW, Holmes GL : Epilepsy and Autism Cold Spring Harb Perspect Med 6 : a022749, 2016
PubMed
8) Sierra-Arregui T, Llorente J, Minguez PG et al : Neurobiological Mechanisms of Autism Spectrum Disorder and Epilepsy, Insights from Animal Models. Neuroscience 445 : 69-82, 2020
 
9) 中川栄二 : てんかん新分類と新規抗てんかん薬の開発. 脳と発達 51 : 91-96, 2019
Medical*Online
10) 中川栄二 : 新しい抗てんかん薬について-それぞれの作用機序, 有効な臨床像, 副作用や相互作用. 小児内科 53 : 1565-1574, 2021
Medical*Online
11) 中川栄二 : 精神症状, 発達障害の薬物療法, 小児科ベストプラクティス 新分類・新薬でわかる小児けいれん・てんかん診療, 浜野晋一郎 (編集), 中山書店, 東京, 2022, pp. 348-357
 
12) 中川栄二 : 自閉スペクトラム症の薬物治療. 発達障害医学の進歩 29集, 日本発達障害連盟, 2017, pp. 1-9
 
13) Villanueva V, Garces M, Lopez-Gonzalez FJ et al : Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting : The FYDATA study. Epilepsy Res 126 : 201-210, 2016
 
14) Shankar R, Henley W, Wehner T et al : Perampanel in the general population and in people with intellectual disability : Differing responses. Seizure 49 : 30-35, 2017
PubMed
15) Wang T, Wen B, Chi Z et al : The well responsiveness of drug-resistant focal seizures in anti-AMPA2 receptor encephalitis to perampanel treatment. Neurol Sci 43 : 525-532, 2022
PubMed
16) Moraes JS, Hepworth G, Ignatiadis S et al : Improved irritability, mood, and quality of life following introduction of perampanel as late adjunctive treatment for epilepsy. Epilepsy Behav 104 (Pt A) : 106883, 2020
 
17) Hasegawa N, Tohyama J : Positive and negative effects of perampanel treatment on psychiatric and behavioral symptoms in adult patients with epilepsy. Epilepsy Behav 117 : 107515, 2021
PubMed
18) 国立精神・神経医療研究センター病院 てんかんセンター (編) : 患者のギモンに答える! てんかん診療のための相談サポート Q&A. 診断と治療社, 東京, 2021
 
P.98 掲載の参考文献
1) French JA, Krauss GL, Wechsler RT et al : Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy A randomized trial. Neurology 85 : 950-957, 2015
PubMed
2) Krauss GL, Serratosa JM, Villanueva V et al : Randomized phase III study 306 : adjunctive perampanel for refractory partial-onset seizures. Neurology 78 : 1408-1415, 2012
PubMed
3) Fogarasi A, Flamini R, Milh M et al : Open-label study to investigate the safety and efficacy of adjunctive perampanel in pediatric patients (4 to < 12 years) with inadequately controlled focal seizures or generalized tonic-clonic seizures. Epilepsia 61 : 125-137, 2020
 
4) Pressler RM, Cilio MR, Mizrahi EM et al : The ILAE classification of seizures and the epilepsies : Modification for seizures in the neonate. Position paper by the ILAE Task Force on Neonatal Seizures. Epilepsia 62 : 615-628, 2021
PubMed
5) Howell KB, Freeman JL, Mackay MT et al : The severe epilepsy syndromes of infancy : A population-based study. Epilepsia 62 : 358-370, 2021
PubMed
6) Kuersten M, Tacke M, Gerstl L et al : Antiepileptic therapy approaches in KCNQ2 related epilepsy : A systematic review. Eur J Med Genet 63 : 103628, 2020
PubMed
7) Ishikawa N, Tateishi Y, Tani H et al : Successful treatment of intractable life-threatening seizures with perampanel in the first case of early myoclonic encephalopathy with a novel de novo SCN1A mutation. Seizure 71 : 20-23, 2019
PubMed
8) Daida A, Hamano SI, Ikemoto S et al : Use of Perampanel and a Ketogerlic Diet in Nonketotic Hyperglycinemia : A Case Report. Neuropediatrics 51 : 417-420, 2020
 
9) 「てんかん診療ガイドライン」作成委員会編, 日本神経学会監修 : てんかん診療ガイドライン 2018, 医学書院, 東京, 2018, pp27-30
 
10) Chang FM, Fan PC, Weng WC et al : The efficacy of perampanel in young children with drug-resistant epilepsy. Seizure 75 : 82-86, 2020
PubMed
11) Yoshitomi S, Takahashi Y, Yamaguchi T et al : Efficacy and tolerability of perampanel in pediatric patients with Dravet syndrome. Epilepsy Res 154 : 34-38, 2019
 
12) Auvin S, Dozieres B, Ilea A et al : Use of perampanel in children and adolescents with Lennox-Gastaut Syndrome. Epilepsy Behav 74 : 59-63, 2017
PubMed
13) Ikemoto S, Hamano SI, Hirata Y et al : Perampanel in lissencephaly-associated epilepsy. Epilepsy Behav Case Rep 11 : 67-69, 2019
PubMed
14) Crespel A, Gelisse P, Tang NP et al : Perampanel in 12 patients with Unverricht-Lundborg disease. Epilepsia 58 : 543-547, 2017
PubMed
15) Goldsmith D, Minassian BA : Efficacy and tolerability of perampanel in ten patients with Lafora disease. Epilepsy Behav 62 : 132-135, 2016
PubMed
16) Shiraishi H, Egawa K, Ito T et al : Efficacy of perarnpanel for controlling seizures and improving neurological dysfunction in a patient with dentatorubral-pallidoluysian atrophy (DRPLA). Epilepsy Behav Case Rep 8 : 44-46, 2017
 
17) Tahara M, Higurashi N, Narita A et al : Long-term efficacy of low-dose perampanel for progressive myoclonus epilepsy in a patient with Gaucher disease type 3. Brain Dev 44 : 308-312, 2022
 
18) Trinka E, Lattanzi S. Carpenter K et al : Exploring the Evidence for Broad-Spectrum Effectiveness of Perampanel : A Systematic Review of Clinical Data in Generalised Seizures. CNS Drugs 35 : 821-837, 2021
PubMed
P.104 掲載の参考文献
1) 日本てんかん学会編集 : てんかん専門医ガイドブック 改訂第2版 てんかんにかかわる医師のための基本知識. 診断と治療社, 東京, 2020, pp. 176-180, pp. 72-273
 
2) 「てんかん診療ガイドライン」作成委員会編集, 日本神経学会監修 : てんかん診療ガイドライン 2018. 医学書院, 東京, 2018, p115, pp. 133-143
 
3) 「精神疾患を合併した, 或いは合併の可能性のある妊産婦の診療ガイド」作成委員会編集, 日本精神神経学会, 日本産科婦人科学会監修 : 精神疾患を合併した, 或いは合併の可能性のある妊産婦の診療ガイド : 各論編. 2022年1月 (第1.2版) (https://www.jspn.or.jp/uploads/uploads/files/activity/Clinical_guide_for_women_with_mental_health_problems_during_perinatal_period_details_ver1.2.pdf)
 
4) Kwan P, Brodie MJ : Early identification of refractory epilepsy. N Engl J Med 342 : 314-319, 2000
PubMed
5) Schiller Y, Najjar Y et al : Quantifying the response to antiepileptic drugs : effect of past treatment history. Neurology 70 : 54-65, 2008
PubMed
6) Tomson T, Battino D, Bonizzoni E et al : Comparative risk of major congenital malformations with eight different antiepileptic drugs : aprospective cohort study of the EURAP registry. Lancet Neurol 17 : 530-538, 2018
 
7) The North American AED Pregnancy Registry. Latest Study Data-May 2022 (https://www.aedpregnancyregistry.org/latest-data/)
 
8) Campbell E, Kennedy F, Russell A et al : Malformation risks of antiepileptic drug monotherapies in pregnancy : updated results from the UK and Ireland Epilepsy and Pregnancy Registers. J Neurol Neurosurg Psychiatry 85 : 1029-1034, 2014
PubMed
9) Tomson T, Battino D, Bonizzoni E et al : Dose-dependent teratogenicity of valproate in mono- and polytherapy : an observational study. Neurology 85 : 866-872, 2015
PubMed
10) Vazquez B, Tomson T, Dobrinsky C et al : Perampanel and pregnancy. Epilepsia 62 : 698-708, 2021
PubMed
11) Leach Jp, Smith PE, Craig J et al : Epilepsy and Pregnancy : For healthy pregnancies and happy outcomes. Suggestions for service improvements from the Multispecialty UK Epilepsy Mortality Group. Seizure 50 : 67-72, 2017
PubMed
12) MacDonald SC, Bateman BT, McElrath TF et al : Mortality and Morbidity During Delivery Hospitalization Among Pregnant Women With Epilepsy in the United States. JAMA Neurol 72 : 981-988, 2015
PubMed
13) 日本産科婦人科学会, 日本産婦人科医会 (編集・監修) : 産婦人科診療ガイドライン 産科編 2020. 日本産科婦人科学会事務局, 東京, 2020
 
14) Tomson T, Battino D, Bonizzoni E et al : Withdrawal of valproic acid treatment during pregnancy and seizure outcome : Observations from EURAP. Epilepsia 57 : e173-e177, 2016
PubMed
15) Craig JJ, Scott S, Leach Jp : Epilepsy and pregnancy : identifying risks. Pract Neurol 22 : 98-106, 2022
PubMed
16) Egawa M, Hara K, Ikeda M et al : Role of obstetricians in promoting pregnancy-related knowledge among women with epilepsy in Japan. Epilepsy Behav 111 : 107176, 2020
PubMed
17) Baishya J, Jose M, A S R et al : Do women with epilepsy benefit from epilepsy specific pre-conception care? Epilepsy Res 160 : 106260, 2020
 
18) Abe K, Hamada H, Yamada T et al : Impact of planning of pregnancy in women with epilepsy on seizure control during pregnancy and on maternal and neonatal outcomes. Seizure 23 : 112-116, 2014
PubMed
19) Otani K : Risk factors for the increased seizure frequency during Pregnancy and puerperium. Folia Psychiatr Neurol Jpn 39 : 33-41, 1985
PubMed
20) Peljto AL, Barker-Cummings C, Vasoli VM et al : Familial risk of epilepsy : a population-based study. Brain 137 : 795-805, 2014
PubMed
P.108 掲載の参考文献
1) 内閣府 : 令和3年版高齢社会白書. [https://www8.cao.go.jp/kourei/whitepaper/w-2021/zenbun/03pdf_index.html]
 
2) GBD 2016 Epilepsy Collaborators : Global, regional, and national burden of epilepsy, 1990-2016 : a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 18 : 357-375, 2019
PubMed
3) Tanaka A, Hata J, Akamatsu N et al : Prevalence of adult epilepsy in a general Japanese population : The Hisayama study. Epilepsia Open 4 : 182-186, 2019
 
4) Bernardi S, Scaldaferri N, Vanacore N et al : Seizures in Alzheimer's disease : aretrospective study of a cohort of outpatients. Epileptic Disord 12 : 16-21, 2010
 
5) Brodie MJ, Kwan P : Epilepsy in elderly people. BMJ 331 : 1317-1322, 2005
PubMed
6) 「てんかん診療ガイドライン」作成委員会編集, 日本神経学会監修 : てんかん診療ガイドライン 2018. 医学書院, 東京, 2018
 
7) Sen A, Jette N, Husain M et al : Epilepsy in older people. Lancet 395 : 735-748, 2020
PubMed
8) Hanada T, Hashizume Y, Tokuhara N et al : Perampanel : a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia 52 : 1331-1340, 2011
PubMed
9) Patel D, Steinberg J, Patel P : Insomnia in the Elderly : A Review. J Clin Sleep Med 14 : 1017-1024, 2018
PubMed
10) Gidal BE, Majid O, Ferry J et al : The practical impact of altered dosing on perampanel plasma concentrations : pharmacokinetic modeling from clinical studies. Epilepsy Behav 35 : 6-12, 2014
PubMed
P.113 掲載の参考文献
1) Roshan S, Puri V, Chaudhry N et al : Sleep abnormalities in juvenile myoclonic epilepsy-A sleep questionnaire and polysomnography based study. Seizure 50 : 194-201, 2017
PubMed
2) Grigg-Damberger M, Andrews N, Wang L et al : Subjective and objective hypersomnia highly prevalent in adults with epilepsy. Epilepsy Behav 106 : 107023, 2020
PubMed
3) Khachatryan SG, Ghahramanyan L, Tavadyan Z et al : Sleep-related movement disorders in a population of patients with epilepsy : prevalence and impact of restless legs syndrome and sleep bruxism. J Clin Sleep Med 16 : 409-414, 2020
 
4) Giuliano L, Mainieri G, Cicero CE et al : Parasomnias, sleep-related movement disorders and physiological sleep variants in focal epilepsy : A polysomnographic study. Seizure 81 : 84-90, 2020
PubMed
5) Durazzo TS, Spencer SS, Duckrow RB et al : Temporal distributions of seizure occurrence from various epileptogenic regions. Neurology 70 : 1265-1271, 2008
PubMed
6) Khan S, Nobili L, Khatami R et al : Circadian rhythm and epilepsy. Lancet Neurol 17 : 1098-1108, 2018
PubMed
7) 加藤元博 : 脳波律動の発現機構 (I). 臨床脳波 40 : 399-405, 1998
 
8) 加藤元博 : 脳波律動の発現機構 (II). 臨床脳波 40 : 467-473, 1998
 
9) Ng M, Pavlova M : Why are seizures rare in rapid eye movement sleep? Review of the frequency of seizures in different sleep stages. Epilepsy Res Treat 2013 : 932790, 2013
PubMed
10) Badawy RAB, Strigaro G, Cantello R : TMS, cortical excitability and epilepsy : the clinical impact. Epilepsy Res 108 : 153-161, 2014
 
11) Manganotti P, Bongiovanni LG, Fuggetta G et al : Effects of sleep deprivation on cortical excitability in patients affected by juvenile myoclonic epilepsy : a combined transcranial magnetic stimulation and EEG study. J Neurol Neurosurg Psychiatry 77 : 56-60, 2006
PubMed
12) Malow BA, Levy K, Maturen K et al : Obstructive sleep apnea is common in medically refractory epilepsy patients. Neurology 55 : 1002-1007, 2000
PubMed
13) Pornsrirliyom D, Shinlapawittayatorn K, Fong J et al : Continuous positive airway pressure therapy for obstructive sleep apnea reduces interictal epileptiform discharges in adults with epilepsy. Epilepsy Behav 37 : 171-174, 2014
 
14) Malow BA, Foldvary-Schaefer N, Vaughn BV et al : Treating obstructive sleep apnea in adults with epilepsy : a randomized pilot trial. Neurology 71 : 572-577, 2008
PubMed
15) Vendrame M, Auerbach S, Loddenkemper T et al : Effect of continuous positive airway pressure treatment on seizure control in patients with obstructive sleep apnea and epilepsy. Epilepsia 52 : e168-e171, 2011
PubMed
16) 紀戸恵介, 谷口浩一郎, 丸本圭一ほか : 閉塞性睡眠時無呼吸症候群を疑う糖尿病長期罹患患者へのパルスオキシメトリによるスクリーニング. 臨床神経生理学 47 : 17-22, 2019
 
17) 立花直子 : 睡眠時無呼吸症候群の診断と検査. 日本医師会雑誌 149 : 261-265, 2020
 
18) Garcia-Borreguero D, Silber MH, Winkelman JW et al : Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation : a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. Sleep Med 21 : 1-11, 2016
PubMed
P.118 掲載の参考文献
1) Maschio M : Brain tumor-related epilepsy. Curr Neuropharmacol 10 : 124-133, 2012
PubMed
2) Shamji MF, Fric-Shamji EC, Benoit BG : Brain tumors and epilepsy : pathophysiology of peritumoral changes. Neurosurg Rev 32 : 275-284, 2009
PubMed
3) Shaw MD, Foy PM : Epilepsy after craniotomy and the place of prophylactic anticonvulsant drugs : discussion paper. J R Soc Med 84 : 221-223, 1991
 
4) van Breelnen MS, Wilms EB, Vecht CJ : Epilepsy in patients with brain tumours : epidemiology, mechanisms, and management. Lancet Neurol 6 : 421-430, 2007
 
5) 「てんかん診療ガイドライン」作成委員会編, 日本神経学会監修 : てんかん診療ガイドライン 2018, 医学書院, 東京, 2018, pp. 27-28
 
6) Roth P, Pace A, Rhun EL et al : Neurological and vascular complications of primary and secondary brain tumours : EANO-ESMO Clinical Practice Guidelines for prophylaxis, diagnosis, treatment and follow-up. Ann Oncol 32 : 171-182, 2021
 
7) Rogawski MA, Tofighy A, White HS et al : Current understanding of the mechanism of action of the antiepileptic drug lacosamide. Epilepsy Res 110 : 189-205, 2015
PubMed
8) Ruda R, Pellerino A, Franchino F et al : Lacosamide in patients with gliomas and uncontrolled seizures : results from an observational study. J Neurooncol 136 : 105-114, 2018
PubMed
9) Motomura K, Chalise L, Shimizu H et al : Intraoperative seizure outcome of levetiracetam combined with perampanel therapy in patients with glioma undergoing awake brain Surgery. J Neurosurg 135 : 998-1007, 2021
 
P.123 掲載の参考文献
1) Lin JJ, Mula M, Hermann BP : Uncovering the neurobehavioural comorbidities of epilepsy over the lifespan. Lancet 380 : 1180-1192, 2012
PubMed
2) Lu E, Pyatka N, Burant CJ et al : Systematic Literature Review of Psychiatric Comorbidities in Adults with Epilepsy. J Clin Neurol 17 : 176-186, 2021
 
3) Mula M Sander JW : Psychosocial aspects of epilepsy : a wider approach. BJPsych Open 2 : 270-274, 2016
PubMed
4) Tadokoro Y, Oshima T, Fukuchi T et al : Screening for major depressive episodes in Japanese patients with epilepsy : validation and translation of the Japanese version of Neurological Disorders Depression Inventory for Epilepsy (NDDI-E). Epilepsy Behav 25 : 18-22, 2012
PubMed
5) Mula M, Kanner AM, Jette N et al : Psychiatric Comorbidities in People With Epilepsy. Neurol Clin Pract 11 : e112-e120, 2021
PubMed
6) Piedad J, Rickards H, Besag FMC et al : Beneficial and adverse psychotropic effects of antiepileptic drugs in patients with epilepsy : a summary of prevalence, underlying mechanisms and data limitations. CNS Drugs 26 : 319-335, 2012
 
7) Chen B, Choi H, Hirsch LJ et al : Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy. Epilepsy Behav 76 : 24-31, 2017
PubMed
8) Steinhoff BJ, Klein P, Klitgaard H et al : Behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate : A systematic review. Epilepsy Behav 118 : 107939. 2021
PubMed
9) Brodie MJ, Kwan P : Current position of phenobarbital in epilepsy and its future. Epilepsia 53 (Suppl 8) : 40-46, 2012
 
10) Calle-Lopez Y, Ladino LD, Benjumea-Cuartas V et al : Forced normalization : A systematic review. Epilepsia 60 : 1610-1618, 2019
PubMed
11) Shih JJ, Whitlock JB, Chimato N et al : Epilepsy treatment in adults and adolescents : Expert opinion, 2016. Epilepsy Behav 69 : 186-222, 2017
PubMed
12) Kanner AM, Bicchi MM : Antiseizure Medications for Adults With Epilepsy : A Review. JAMA 327 : 1269-1281, 2022
PubMed
13) Seiden LG, Connor GS : The importance of drug titration in the management of patients with epilepsy. Epilepsy Behav 128 : 108517, 2022
PubMed
14) Altalib HH, Berg AT, Cong X et al : Presurgical depression and anxiety are not associated with worse epilepsy surgery outcome five years postoperatively. Epilepsy Behav 83 : 7-12, 2018
 
15) Nishida T, Usui N, Inoue Y et al : Presurgical depression and anxiety are not associated with worse epilepsy surgery outcome five years postoperatively, Epilepsy Behav 122 : 108216, 2021
 
16) Conway CR, Udaiyar A, Schachter SC : Neurostimulation for depression in epilepsy. Eoilepsy Behav 88 (supplement) : S25-S32, 2018
 
17) Ruiz-Gimenez J, Sanchez-Alvarez JC. Cafiadillas-Hidalgo F et al : Antiepileptic treatment in patients with epilepsy and other comorbidities. Seizure 19 : 375-382, 2010
 
18) Kanner AM : Most antidepressant drugs are safe for patients with epilepsy at therapeutic doses : A review of the evidence. Epilepsy Behav 61 : 282-286, 2016
PubMed
19) Perucca E : Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 61 : 246-255, 2005
 
20) Agrawal N, Mula M : Treatment of psychoses in patients with epilepsy : an update. Ther Adv Psychopharmacol 9 : 1-10, 2019
 
21) 中村元昭 : 反復経頭蓋磁気刺激 (rTMS) 療法の適正使用指針-背景にある考え方-, 精神神経学雑誌 121 : 395-404, 2019
 
P.130 掲載の参考文献
1) Carney N, Totten AM, O'Reilly C et al : Guidelines for the Management of Severe Traumatic Brain Injury. Fourth Edition. Neurosurgery 80 : 6-15, 2017
 
2) 稲次基希, 橋本聡華, 山村俊弘ほか : 重症頭部外傷後けいれんの検討 : 日本頭部外傷データバンクプロジェクト2015の分析. 神経外傷 42 : 189-194, 2019
 
3) Jensen FE : Introduction. Posttraumatic epilepsy : treatable epileptogenesis. Epilepsia 50 (Suppl 2) : 1-3, 2009
 
4) Ritter AC, Wagner AK, Fabio A et al : Incidence and risk factors of posttraumatic seizures following traumatic brain injury : A Traumatic Brain Injury Model Systems Study. Epilepsia 57 : 1968-1977, 2016
PubMed
5) Kubota Y, Nakamoto H, Kawamata T : Nonconvulsive Status Epilepticus in the Neurosurgical Setting. Neurol Med Chir 56 : 626-631, 2016
PubMed
6) Claassen J, Vespa P, Participants in the International Multi-disciplinary Consensus Conference on Multimodality Monitoring : Electrophysiologic monitoring in acute brain injury. Neurocrit Care 21 (Suppl 2) : S129-S147, 2014
 
7) 日本脳神経外科学会/日本脳神経外傷学会監修, 頭部外傷治療・管理のガイドライン作成委員会編集 : 頭部外傷治療・管理のガイドライン 第4版. 医学書院, 東京. 2019
 
8) Temkin NR : Risk factors for posttraumatic seizures in adults. Epilepsia 44 (s10) : 18-20, 2003
PubMed
9) Frey LC : Epidemiology of posttraumatic epilepsy : a critical review. Epilepsia 44 (s10) : 11-17, 2003
PubMed
10) Tanaka T, Litofsky NS : Anti-epileptic drugs in pediatric traumatic brain injury. Expert Rev Neurother 16 : 1229-1234, 2016
PubMed
11) Leitinger M, Beniczky S, Rohracher A et al : Salzburg Consensus Criteria for Non-Convulsive Status Epilepticus-approach to clinical application. Epilepsy Behav 49 : 158-163, 2015
PubMed
12) 「てんかん診療ガイドライン」作成委員会編集, 日本神経学会監修 : てんかん診療ガイドライン 2018. 医学書院, 東京, 2018
 
13) Hara K, Haranishi Y, Terada T : Intrathecally administered perampanel alleviates neuropathic and inflammatory pain in rats. Eur J Pharmacol 872 : 172949, 2020
PubMed
14) Meyfroidt G, Baguley IJ, Menon DK : Paroxysmal sympathetic hyperactivity : the storm after acute brain injury. Lancet Neurol 16 : 721-729, 2017
PubMed

Part 5 社会参加・復帰に向けたてんかん治療

P.136 掲載の参考文献
1) 廣實真弓 : 失語なのか非失語なのか-失語症の人へのアプローチとてんかんのある人へのアプローチ. 高次脳機能研究 38 : 172-176, 2018
 
2) 廣實真弓 : 成人の高次脳機能障害はどのように評価・介入をしますか? てんかん支援 Q&A リハビリ・生活支援の実践, 谷口豪, 西田拓司, 廣實真弓 (編著), 医歯薬出版, 東京, 2018, pp. 94-98
 
3) 厚生労働省 : 障害者雇用対策. [https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/koyou_roudou/koyou/shougaishakoyou/index.html] (2022年3月閲覧)
 
P.140 掲載の参考文献
1) 伊藤正利, 井上有史, 栗原まなほか : てんかんをもつ人と運転免許. 小児科臨床 57 : 1689-1697, 2004
Medical*Online
2) 井上有史 : てんかんの既往歴と産業車両運転業務. 日本医事新報 4334 : 92-93, 2007
 
3) Nishida T, Kawai K, Tachimori H : Risks of seizure with fatal traffic crash at wheel in people with epilepsy. Seizure 76 : 110-115, 2020
PubMed
P.144 掲載の参考文献
1) Wang D, Hu B, Hu C et al : Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 323 : 1061-1069. 2020
PubMed
2) Chen T, Wu D, Chen H et al : Clinical characteristics of 113 deceased patients with coronavirus disease 2019 : retrospective study. BMJ 368 : m1091, 2020
PubMed
3) CDC COVID-19 Response Team : Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019-United States, February 12-March 28, 2020. MMWR Morb Mortal Wkly Rep 69 : 382-386, 2020
 
4) Mao L, Jin H, Wang M et al : Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol 77 : 683-690, 2020
 
5) French JA, Brodie MJ, Caraballo R et al : Keeping people with epilepsy safe during the COVID-19 pandemic. Neurology 94 : 1032-1037, 2020
PubMed
6) American Epilepsy Society (AES) : Survey Impact of COVID-19 Pandemic on Epilepsy Care Summary of Results. August 24, 2020 (https://www.aesnet.org/sites/default/files/file_attach/2020-09-02-COVID_Survey-Web_summary-final.pdf)
 
7) Lu L, Xiong W, Liu D et al : New onset acute symptomatic seizure and risk factors in coronavirus disease 2019 : Aretrospective multicenter study. Epilepsia 61 : e49-e53, 2020
 
8) Moriguchi T, Harii N, Goto J et al : A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. Int J Infect Dis 94 : 55-58, 2020
PubMed
9) 日本てんかん学会, 日本臨床神経生理学会, 日本脳神経外科学会ほか : COVID-19感染予防対策として. 脳波検査に関する注意喚起. 2020年4月7日 (https://square.umin.ac.jp/jes/images/COVID%2019_472020.pdf)
 
10) Child neurology society : Management of infantile spasms during the covid-19 pandemic. (https://www.childneurologysociety.org/resources/resources-detail-view/management-of-infantile-spasms-during-the-covid-19-pandemic) (アクセス 2020年10月19日)
 
11) Ferrazzi EM, Frigerio L, Cetin I et al : COVID-19 Obstetrics Task Force. Lombardy, Italy : Executive management summary and short report of outcome. Int J Gynaecol Obstet 149 : 377-378, 2020
PubMed
12) Lai SL, Hsu MT, Chen SS : The impact of SARS on epilepsy : the experience of drug withdrawal in epileptic patients. Seizure 14 : 557-561, 2005
PubMed

Part 6 AMPA型グルタミン酸受容体拮抗薬の今後の展望 - 薬理学的な特徴とリポジショニング -

P.150 掲載の参考文献
1) Marin B, Boumediene F, Logroscino G et al : Variation in worldwide incidence of amyotrophic lateral sclerosis : a meta-analysis. Int J Epidemiol 46 : 57-74, 2017
PubMed
2) Robberecht W, Philips T : The changing scene of amyotrophic lateral sclerosis. Nat Rev Neurosci 14 : 248-264, 2013
PubMed
3) Chio A, Logroscino G, Traynor BJ et al : Global epidemiology of amyotrophic lateral sclerosis : a systematic review of the published literature. Neuroepidemiology 41 : 118-130, 2013
PubMed
4) Brown RH, Al-Chalabi A : Amyotrophic Lateral Sclerosis. N Engl J Med 377 : 162-172, 2017
PubMed
5) Traynelis SF, Wollmuth LP, McBain CJ et al : Glutamate receptor ion channels : structure, regulation, and function. Pharmacol Rev 62 : 405-496, 2010
PubMed
6) Weiss JH, Choi DW : Slow non-NMDA receptor mediated neurotoxicity and amyotrophic lateral sclerosis. Adv Neurol 56 : 311-318, 1991
PubMed
7) Carriedo SG, Yin HZ, Weiss JH : Motor neurons are selectively vulnerable to AMPA/kainate receptor-mediated injury in vitro. J Neurosci 16 : 4069-4079, 1996
PubMed
8) Van Den Bosch L, Vandenberghe W, Klaassen H et al : Ca (2+) -permeable AMPA receptors and selective vulnerability of motor neurons. J Neurol Sci 180 : 29-34, 2000
PubMed
9) Higuchi M, Maas S, Single FN et al : Point mutation in an AMPA receptor gene rescues lethaiity in mice deficient in the RNA-editing enzyme ADAR2. Nature 406 : 78-81, 2000
 
10) Takuma H, Kwak S, Yoshizawa T et al : Reduction of GluR2 RNA editing, a molecular change that increases calcium influx through AMPA receptors, selective in the spinal ventral gray of patients with amyotrophic lateral sclerosis. Ann Neurol 46 : 806-815, 1999
PubMed
11) Kawahara Y, Ito K, Sun H et al : RNA editing and death of motor neurons. Nature 427 : 801, 2004
PubMed
12) Hideyama T, Yamashita T, Aizawa H et al : Profound downregulation of the RNA editing enzyme ADAR2 in ALS spinal motor neurons. Neurobiol Dis 45 : 1121-1128, 2012
PubMed
13) Aizawa H, Sawada J, Hideyama T et al : TDP-43 pathology in sporadic ALS occurs in motor neurons lacking the RNA editing enzyme ADAR2. Acta Neuropathol 120 : 75-84, 2010
PubMed
14) Greger IH, Khatri L, Kong X et al : AMPA receptor tetramerization is mediated by Q/R editing. Neuron 40 : 763-774, 2003
 
15) Yamashita T, Kwak S : Cell death cascade and molecular therapy in ADAR2-deficient motor neurons of ALS. NVeurosci Res 144 : 4-13, 2019
PubMed
16) Hideyama T, Yamashita T, Suzuki T et al : Induced loss of ADAR2 engenders slow death of motor neurons from Q/R site-unedited GluR2. J Neurosci 30 : 11917-11925, 2010
 
17) Yamashita T, Hideyama T, Hachiga K et al : A role for calpain-dependent cleavage of TDP-43 in amyotrophic lateral sclerosis pathology. Nat Commun 3 : 1307, 2012
PubMed
18) Hideyama T, Teramoto S, Hachiga K et al : Co-occurrence of TDP-43 mislocalization with reduced activity of an RNA editing enzyme, ADAR2, in aged mouse motor neurons. PLoS One 7 : e43469, 2012
PubMed
19) Arai T, Hasegawa M, Akiyama H et al : TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 351 : 602-611, 2006
PubMed
20) Neumann M, Sampathu DM, Kwong LK et al : Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314 : 130-133, 2006
 
21) Yamashita T, Aizawa H, Teramoto S et al : Calpain-dependent disruption of nucleo-cytoplasmic transport in ALS motor neurons. Sci Rep 7 : 39994, 2017
PubMed
22) Aizawa H, Yamashita T, Kato H et al : Impaired Nucleoporins Are Present in Sporadic Amyotrophic Lateral Sclerosis Motor Neurons that Exhibit Mislocalization of the 43-kDa TAR DNA-Binding Protein. J Clin Neurol 15 : 62-67, 2019
PubMed
23) Yamashita T, Chai HL, Teramoto S et al : Rescue of amyotrophic lateral sclerosis phenotype in a mouse model by intravenous AAV9-ADAR2 delivery to motor neurons. EMBO Mol Med 5 : 1710-1719, 2013
 
24) Akamatsu M, Yamashita T, Hirose N et al : The AMPA receptor antagonist perampanel robustly rescues amyotrophic lateral sclerosis (ALS) pathology in sporadic ALS model mice. Sci Rep 6 : 28649, 2016
PubMed
25) Hanada T, Hashizume Y, Tokuhara N et al : Perampanel : a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia 52 : 1331-1340, 2011
PubMed
26) Rogawski MA, Hanada T : Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist. Acta Neurol Scand Suppl 197 : 19-24, 2013
 
27) Steinhoff BJ, Ben-Menachem E, Ryvlin P et al : Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures : a pooled analysis of three phase III studies. Epilepsia 54 : 1481-1489, 2013
PubMed
28) Aizawa H, Kato H, Oba K et al : Randomized phase 2 study of perampanel for sporadic amyotrophic lateral sclerosis. J Neurol 269 : 885-896, 2022
PubMed
29) Lai MC, Tzeng RC, Huang CW et al : The Novel Direct Modulatory Effects of Perampanel, an Antagonist of AMPA Receptors, on Voltage-Gated Sodium and M-type Potassium Currents. Biomolecules 9 : 638, 2019
 
30) Kim JE, Choi HC, Song HK et al : Perampanel Affects Up-Stream Regulatory Signaling Pathways of GluA1 Phosphorylation in Normal and Epileptic Rats. Front Cell Neurosci 13 : 80, 2019
PubMed
31) Akamatsu M, Yamashita T, Teramoto S et al : Testing of the therapeutic efficacy and safety of AMPA receptor RNA aptamers in an ALS mouse model. Life Sci Alliance 5 : e202101193, 2022
 
P.155 掲載の参考文献
1) Suzuki H, Kawakita F, Asada R et al : Oid but still hot target, glutamate-mediated neurotoxicity in stroke. Transl Stroke. Res 13 : 216-217, 2022
 
2) Choi DW : Excitotoxicity : still hammering the ischemic brain in 2020. Front Neurosci 14 : 579953, 2020
PubMed
3) Suzuki H, Kawakita F, Asada R : Neuroelectric mechanisms of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. Int J Mol Sci 23 : 3102, 2022
PubMed
4) Scheefhals N, MacGillavry HD : Functional organization of postsynaptic glutamate receptors. Mol Cell Neurosci 91 : 82-94, 2018
PubMed
P.163 掲載の参考文献
1) Osuka S, Van Meir EG : Overcoming therapeutic resistance in glioblastoma : the way forward. J Clin Invest 127 : 415-426, 2017
 
2) Hara A, Kanayama T, Noguchi K et al : Treatment Strategies Based on Histological Targets against Invasive and Resistant Glioblastoma. J Oncol 2019 : 2964783, 2019
PubMed
3) Barria A : Dangerous liaisons as tumour cells form synapses with neurons. Nature 573 : 499-501, 2019
PubMed
4) Maus A, Peters GJ : Glutamate and α-ketoglutarate : key players in glioma metabolism. Amino Acids 49 : 21-32, 2017
 
5) Ye ZC, Sontheimer H : Glioma cells release excitotoxic concentrations of glutamate. Cancer Res 59 : 4383-4391, 1999
PubMed
6) Ishiuchi S, Yoshida Y, Sugawara K et al : Ca2+ -permeable AMPA receptors regulate growth of human glioblastoma via Akt activation. J Neurosci 27 : 7987-8001, 2007
PubMed
7) Takano T, Lin JH, Arcuino G et al : Glutamate release promotes growth of malignant gliomas. Nat Med 7 : 1010-1015, 2001
PubMed
8) Vanhoutte N, Hermans E : Glutamate-induced glioma cell proliferation is prevented by functional expression of the glutamate transporter GLT-1. FEBS Lett 582 : 1847-1852, 2008
PubMed
9) Ye ZC, Rothstein JD, Sontheimer H : Compromised glutamate transport in human glioma cells : reduction-mislocalization of sodium-dependent glutamate transporters and enhanced activity of cystine-glutamate exchange. J Neurosci 19 : 10767-10777, 1999
 
10) Chung WJ, Sontheimer H : Sulfasalazine inhibits the growth of primary brain tumors independent of nuclear factor-kappaB. J Neurochem 110 : 182-193, 2009
PubMed
11) de Groot JF, Liu TJ, Fuller G et al : The excitatory amino acid transporter-2 induces apoptosis and decreases glioma growth in vitro and in vivo. Cancer Res 65 : 1934-1940, 2005
PubMed
12) Labrakakis C, Patt S, Hartmann J et al : Glutamate receptor activation can trigger electrical activity in human glioma cells. Eur J Neurosci 10 : 2153-2162, 1998
PubMed
13) Markert JM, Fuller CM, Gillespie GY et al : Differential gene expression profiling in human brain tumors. Physiol Genomics 5 : 21-33, 2001
PubMed
14) Ishiuchi S, Tsuzuki K, Yoshida Y et al : Blockage of Ca2+- permeable AMPA receptors suppresses migration and induces apoptosis in human glioblastoma cells. Nat Med 8 : 971-978, 2002
 
15) Maas S, Patt S, Schrey M et al : Underediting of glutamate receptor GluR-B mRNA in malignant gliomas. Proc Natl Acad Sci U S A 98 : 14687-14692, 2001
PubMed
16) Sontheimer H : Malignant gliomas : perverting glutamate and ion homeostasis for selective advantage. Trends Veurosci 26 : 543-549, 2003
PubMed
17) Smith JS, Tachibana I, Passe SM et al : PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 93 : 1246-1256, 2001
PubMed
18) Lokker NA, Sullivan CM, Hollenbach SJ et al : Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells : evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res 62 : 3729-3735, 2002
PubMed
19) Shawver LK, Slamon D, Ullrich A : Smart drugs : tyrosine kinase inhibitors in cancer therapy. Cancer Cell 1 : 117-123, 2002
 
20) Datta SR, Brunet A, Greenberg ME : Cellular survival : a play in three Akts. Genes Dev 13 : 2905-2927, 1999
PubMed
21) Alessi DR, Cohen P : Mechanism of activation and function of protein kinase B. Curr Opin Genet Dev 8 : 55-62, 1998
PubMed
22) Osaki M, Oshimura M, Ito H : PI3K-Akt pathway : its functions and alterations in human cancer. Apoptosis 9 : 667-676, 2004
PubMed
23) Cantley LC, Neel BG : New insights into tumor suppression : PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci U S A 96 : 4240-4245, 1999
PubMed
24) Li J, Yen C, Liaw D et al : PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275 : 1943-1947, 1997
PubMed
25) Maehama T, Dixon JE : The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3, 4, 5-trisphosphate. J Biol Chem 273 : 13375-13378, 1998
PubMed
26) Choe G, Horvath S, Cloughesy TF et al : Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 63 : 2742-2746, 2003
PubMed
27) Toker A, Newton AC : Akt/protein kinase B is regulated by autophosphorylation at the hypothetical PDK-2 site. J Biol Chem 275 : 8271-8274, 2000
 
28) Vanhaesebroeck B, Alessi DR : The PI3K-PDK1 connection : more than just a road to PKB. Biochem J 346 (Pt 3) : 561-576, 2000
PubMed
29) Mellinghoff IK, Wang MY, Vivanco I et al : Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353 : 2012-2024, 2005
PubMed
30) Allen NJ, Barres BA : Neuroscience : Glia-more than just brain glue. Nature 457 : 675-677, 2009
PubMed
31) Venkataramani V, Tanev DI, Strahle C et al : Glutamatergic synaptic input to glioma cells drives brain tumour progression. Nature 573 : 532-538, 2019
PubMed
32) Venkatesh HS, Morishita W, Geraghty AC et al : Electrical and synaptic integration of glioma into neural circuits. Nature 573 : 539-545, 2019
PubMed
33) Rogawski MA, Hanada T : Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist. Acta Neurol Scand Suppl 197 : 19-24, 2013
 
34) Loscher W, Schmidt D : Epilepsy : perampanel-new promise for refractory epilepsy? Nat Rev Neurol 8 : 661-662, 2012
PubMed
P.168 掲載の参考文献
1) Polymeropoulos MH, Lavedan C, Leroy E et al : Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276 : 2045-2047, 1997
PubMed
2) Spillantini MG, Schmidt ML, Lee VM et al : Alpha-synuclein in Lewy bodies. Nature 388 : 839-840, 1997
PubMed
3) Singleton AB, Farrer M, Johnson J et al : alpha-Synuclein locus triplication causes Parkinson's disease. Science 302 : 841, 2003
PubMed
4) Twohig D, Nielsen HM : α-synuclein in the pathophysiology of Alzheimer's disease. Mol Neurodegener 14 : 23, 2019
 
5) Mehra S, Sahay S, Maji SK : α-Synuclein misfolding and aggregation : Implications in Parkinson's disease pathogenesis. Biochim Biophys Acta Proteins Proteom 1867 : 890-908, 2019
 
6) Braak H, Tredici KD, RUb U et al : Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24 : 197-211, 2003
 
7) Luk KC, Kehm V, Carroll J et al : Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338 : 949-953, 2012
 
8) Wu JW, Hussaini SA, Bastille IM et al : Neuronal activity enhances tau propagation and tau pathology in vivo. Nat Neurosci 19 : 1085-1092, 2016
 
9) Angot E, Brundin P : Dissecting the potential mdecular mechanisms underlying alpha-synuclein cell-to-cell transfer in Parkinson's disease. Parkinsonism Relat Disord 15 (Suppl 3) : S143-S147, 2009
 
10) Holmes BB, DeVos SL, Kfoury N et al : Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc Natl Acad Sci U S A 110 : E3138-E3147, 2013
PubMed
11) Uemura N, Uemura MT, Lo A et al : Slow Progressive Accumulation of Oligodendroglial Alpha-Synuclein (α-Syn) Pathology in Synthetic α-Syn Fibril-Induced Mouse Models of Synucleinopathy. J Neuropathol Exp Neurol 78 : 877-890, 2019
 
12) Rey NL, Petit GH, Bousset L et al : Transfer of human α-synuclein from the olfactory bulb to interconnected brain regions in mice. Acta Neuropathol 126 : 555-573, 2013
 

書評

最近チェックした商品履歴

Loading...